ArticleTranslational cancer research2025
Efficacy and safety of toripalimab in the treatment of patients with non-small cell lung cancer: a systematic review and meta-analysis.
Article in Translational cancer research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: For patients with non-small cell lung cancer (NSCLC), the choice of inhibitors remains a controversial issue. Consequently, to evaluate the safety and efficacy of toripalimab, a programmed cell death protein-1 (PD-1) inhibitor, in treating patients with NSCLC, this meta-analysis was performed. Methods: Cochrane Library, Embase, PubMed, and Web of Science were searched to find studies on patients with NSCLC receiving toripalimab. Our study encompassed single-arm studieÓs and randomized controlled trials (RCTs) for analysis. The cut-off date for data collection was March 21, 2024. Data analysis was performed using RStudio. Results: Seven studies were included for analysis, comprising two RCTs and five single-arm studies, all of which were high-quality publications. The results from RCTs demonstrated that toripalimab plus chemotherapy did not increase patients' overall survival (OS), compared with chemotherapy alone [1-year OS: relative risk (RR) =1.05, 95% confidence interval (CI): 0.97-1.13; P=0.37]; [(2-year OS: RR =1.27, 95% CI: 0.89-1.80; P=0.69); P=0.37]. Single-arm studies showed that toripalimab achieved an overall response rate (ORR) of 55.8% (95% CI: 23.9-85.4% ). The OS was 66.3% at 1 year (95% CI: 47.7-82.6%) and 5.9% at 2 years (95% CI: 0.2-18.7%). The disease control rate (DCR) was 85.3% (95% CI: 56.8-100%). In addition, the pathological complete response (pCR) for these patients undergoing neoadjuvant immunochemotherapy with toripalimab was 31.5% (95% CI: 20.4-45.1%). Conclusions: Toripalimab showed promising potential in treating NSCLC. For patients undergoing perioperative neoadjuvant immunochemotherapy, it demonstrated significant efficacy and safety. However, additional RCTs are needed to substantiate our findings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.